Sciferon is used to treat the following diseases:

1. Chronic viral hepatitis B and C
2. Venereal warts
3. Shingles in cancer patients
4. Herpes simplex keratoconjunctivitis of the cornea
5. HIV

SciFeron can be used in the following indications:

1. Malignant melanoma
2. Hairy cell leukaemia
3. AIDS-related Kaposi's sarcoma

The therapeutic efficacy of Sci-Feron™ is believed to be due to four different biological effects: anti-viral, anti-proliferative, differentiation-inducing and immunomodulatory.

The antiviral and immunomodulatory effects of SciFeron™ or other different forms of recombinant interferon are in clinical trials for a number of other viral and metastatic diseases, including hepatitis A, HIV, and a number of blood and solid tumour cancers.

The unwanted host response that appears to occur after prolonged treatment with less pure forms of recombinant interferon is less likely with SciFeron™ due to its higher purity.

The higher purity of SciFeron™ may also lead to lower dosing requirements and an increase in the product yield, representing both a clinical advantage and a price advantage over existing interferon.
As of late 2005, SciFeron™ is ready for clinical trials and we anticipate continued clinical development.